INTRODUCTION
============

In rheumatoid arthritis (RA), inflammation and infiltration of mononuclear cells contribute to synovial hyperplasia ([@R1]). The key regulatory factors for inflammation in RA are TNF-α and IL-1β, but IL-6 or IL-8 contribute to the RA pathology as well ([@R2]--[@R5]). IL-6 is a key factor for activation of B- and T-cells and for the mobilization of neutrophils ([@R6], [@R7]). IL-8 promotes chemotaxis of neutrophils ([@R8]), lymphocytes ([@R9]) and mononuclear cells ([@R10]).

Laminin-111, previously called laminin-1 (LN-1) or EHS laminin, was detected in the pericellular matrix of articular cartilage ([@R11]). Using an anti-EHS-laminin antibody, high expression of laminins has been detected in the lining layer of the synovial membrane of RA patients ([@R12]). Activation of synovial fibroblasts (SF) by binding to LM-111 in the presence of TGF-β1 activated the expression of MMP-3, MMP-10 and IL-16 ([@R13], [@R14]). This activation of SF by TGF-β1 and LM-111 works in the absence of TNF-α and IL-1β does not depend on NFκB signalling, and thus may contribute to tissue destruction in the joints of RA patients, even after administration of pharmaceuticals controlling bioactive TNF-α or IL-1β.

High expression of IL-6, IL-8 and IL-16 were measured in RA synovial fluid ([@R15], [@R16]), and the activation of SF by LM-111 in the presence of TGF-β1 resulted in a significant IL-16 expression ([@R14]). Therefore, we extended our recent studies and investigated whether LM-111 and TGF-β1 cooperate in regulation of additional RA-associated interleukins in SF, specifically of IL-6 and IL-8.

METHODS
=======

Cell culture
------------

SF were isolated from synovial tissue of 17 OA and 16 RA patients as described recently (Table [1](#T1){ref-type="table"}) ([@R14]). The cells were expanded in DMEM medium (Life Technologies) enriched with ITS (Life Technologies), 10% FCS (Biochrome) and antibiotics (Sigma). This study was approved by the local ethics committee.

###### 

Clinical data of patients included in the study

  Diagnosis   Number of patients   Gender of patients   Mean age   Mean CRP   Mean BSR   DMARDs   Steriods   NSAR
  ----------- -------------------- -------------------- ---------- ---------- ---------- -------- ---------- -------
                                                                                                             
  RA          16                   F9/M7                61.8       0.77       29.1       13/16    10/16      4/16
  OA          17                   F9/M8                66.5       0.40       14.5       0/17     1/17       12/17

RA, rheumatoid arthritis; OA, osteoarthritis; F, female; M, male; CRP, C-reactive protein; BSR, blood sedimentation rate; DMARDs, disease modifying anti-rheumatic drugs; NSAR, non-steroidal anti-inflammatory drugs.

For activation, SF were incubated in DMEM complete medium in the presence of rhTGF-β1 (10 ng/mL, 24 h, Calbiochem). Cells in medium without TGF-β1 served as controls. In other experiments, cells were incubated for 24 h in flasks coated with LM-111 (BD Biosciences). Uncoated flasks and flasks coated with LM-511/521 (Chemicon) served as controls.

Transcript analysis
-------------------

RNA was extracted (RNeasy, Qiagen) and cDNA was generated by oligo-(dT) priming and AMV-reverse transcriptase (Clontech) as described ([@R14]). Transcripts were quantified by qRT-PCR utilizing commercially available primers (SearchLC) and normalized to GAPDH and serial dilutions of a recombinant standard (Roche) in each run ([@R17]). The results are presented as mean transcript induction index of activated fibroblasts normalized to the mock-treated cells and the recombinant standards.

Protein analysis
----------------

Production of cytokines was detected in SF supernatants by a multiplexed cytokine array technique (Luminex^®^). Cells were activated for 24 h by the addition of 10 ng/mL rhTGF-β1, by binding to coated LM-111 or by binding to LM-111 in the presence of TGF-β1. Controls were incubated in normal tissue culture flasks without stimuli. Supernatants were harvested and pre-cleared by centrifugation (12000 x g, 4°C, 5 min), and aliquots were mixed with dye-loaded microbeads coated with antibodies reactive with the cytokines followed by biotinylated detection antibodies and fluorochrome-labelled detection reagent for quantification (Invitrogen). The cytokine array data were confirmed by ELISA (λscan Bio-Tek) and commercially available kits (GE Health Care).

Biological activity of IL-6 was confirmed by the B9 B-cell hybridoma proliferation assay (a generous gift of Prof. Kolodziej, Berlin). Briefly, supernatants of activated SF (n=8) were added to B9 cells and IL-6-dependent cell proliferation was determined utilizing a modified MTT assay (EZ4U, Biomedica). Complete medium and dilutions of rhIL-6 (GE Health Care) served as controls. Activity of IL-8 was determined by a transmembrane cell mobility assay, in which supernatants of activated cells were added in a modified Boyden chamber and the number of HL-60 cells migrating through the membrane was counted ([@R18]). Complete medium and dilutions of rhIL-8 (GE Health Care) served as controls.

Statistics
----------

The statistical evaluation of the experimental data was performed using a two-sided t-test. The probability values (p) equal to or less than 0.05 (\*), 0.01 (\*\*) or 0.001 (\*\*\*) were considered to be statistically significant and marked in the figures accordingly. The data present the mean values ± standard deviations of individual experiments with cells of n patients (14≥n≥3).

RESULTS
=======

Activation of interleukin mRNA expression in synovial fibroblasts
-----------------------------------------------------------------

Activation of SF by attachment to LM-111 induced a moderate but significant IL-8 mRNA response when compared to SF attached to tissue culture polystyrene (TCPS) flasks. The induction of IL-6 mRNA by LM-111 was low and did not reach significance (induction index ≤2, Fig. [1](#F1){ref-type="fig"}). Binding of SF to LM-511/521 served as a control but failed to activate the expression of the interleukins investigated (not shown). TGF-β1 induced a moderate but significant IL-6 transcript response and a low but significant IL-8 response (Fig. [1](#F1){ref-type="fig"}). Activation of SF by attachment to LM-111 in the presence of TGF-β1 induced significant mRNA responses for IL-6 and IL-8 (Fig. [1](#F1){ref-type="fig"}).

![Regulation of expression of interleukins in synovial fibroblasts. Synovial fibroblasts were incubated for 24 h in TCPS flasks (control), in flasks coated with LM-111, in TCPS flasks in presence of 10 ng/ml TGF-β1 or in flasks coated with LM-111 and in addition activated by 10 ng/ml TGF-β1. The induction of mRNA encoding IL-6 (grey bars) and IL-8 (black bars) was investigated by qRT-PCR. Binding to LM-111 induced a moderate IL-8 response (3.1 ± 1.24; *p*\<0.001) but no IL-6 response (1.3 ± 0.3, *p*\>0.007) in comparison to the TCPS controls. Activation of SF by TGF-β1 induced a moderate and significant IL-6 response (3.6 ± 2.2, *p*\<0.001), whereas IL-8 displayed a significant but very low response (2.2 ± 0.5, *p*\<0.001) in comparison to TCPS controls. Binding of SF to LM-111 in the presence of TGF-β1 induced IL-6 (3.3 ± 1.4, *p*\<0.001) and IL-8 (4.9 ± 2.3, *p*\>0.001) significantly. Statistically significant differences among the three experimental groups are marked by crossbars. The data represent the mean transcript amounts ± standard deviations in cDNA of SF from n patients (11\<n\<14) and are presented as the normalized transcript induction index over mock-treated SF as controls.](IJBS-06-289-g001){#F1}

Production of interleukins by activated synovial fibroblasts
------------------------------------------------------------

The production of cytokines by activated SF was investigated by a multiplexed array (Fig. [2A](#F2){ref-type="fig"}). Activation of SF by TGF-β1 significantly raised the cytokine induction index for IL-6 and IL-8. Co-activation of SF by LM-111 and TGF-β1 further enhanced the release of IL-6 and IL-8 (Fig. [2A](#F2){ref-type="fig"}). The concentrations measured for IL-10 (c~max~\<0.5 pg/ml), IL-12 (c~max~\<2 pg/ml), and TNF-α (c~max~\<0.5 pg/ml) were at or below the detection levels. The maximal IL-1β concentrations were measured at 13 pg/ml (not shown).

The production of IL-6 and IL-8 by activated SF was confirmed by ELISA. The addition of TGF-β1 significantly enhanced the production of IL-6 and IL-8, and co-stimulation of SF by LM-111 and TGF-β1 further enhanced IL-6 and IL-8 production (Fig. [2B](#F2){ref-type="fig"}). The maximal concentration of IL-1β as determined by ELISA remained close to 10 pg/ml in all supernatants investigated (not shown). In SF from 2 out of 8 donors no IL-8 production was detected, but IL-6 was recorded. The reason for this partial unresponsiveness must be clarified in additional investigations.

![Detection of interleukins in supernatants of synovial fibroblasts. A, SF were incubated for 24 h in uncoated TCPS flasks or in LM-111 coated flasks. We screened for cytokines in the SF supernatants by a multiplexed protein array (Luminex^®^). Growth of SF on LM-111 failed to boost the production of IL-6 (grey bars) and IL-8 (black bars). Activation of SF by TGF-β1 (w/o LM-111) significantly raised the cytokine release of IL-6 (3.9-fold ± 1.8, *p*\<0.001) and IL-8 (5.3-fold ± 1.2, *p*\<0.02) compared to mock-treated controls (TCPS). Co-activation of SF by TGF-β1 and LM-111 further enhanced the release of IL-6 (4.6-fold ± 2.1, *p*\<0.001) and IL-8 (9.1-fold ± 1.56, *p*\<0.001). The LM-111 plus TGF-β-induced production of IL-8 was significantly higher than the TGF-β (*p*\<0.02) or LM-111- (*p*\<0.002) induced responses (black crossbars). The TGF-β- and the LM-111 plus TGF-β- induced production of IL-6 were significantly higher (*p*\<0.001 each) than the LM-111- induced response (grey crossbars). Data represent the normalized mean induction index ± standard deviation of interleukin concentrations measured in triplicates over controls (TCPS). B, SF were incubated for 24 h in uncoated TCPS flasks (=control), in TCPS flasks in medium enriched with 10 ng/ml TGF-β1, or in LM-111 coated flasks in medium enriched with 10 ng/ml TGF-β1 as indicated. We measured the concentrations of IL-6 (grey bars, scale to the right) and IL-8 (black bars, scale to the left) in the supernatants by ELISA. In TCPS flasks SF produced spontaneously 1.7 ± 1.1 ng/ml of IL-6 and 25.8 ± 18.4 ng/ml of IL-8. Addition of TGF-β1 significantly stimulated the production of IL-6 (6.2 ng/ml ± 3.9, *p*\<0.008) and IL-8 (65.4 ng/ml ± 31.4, *p*\<0.02). Co-stimulation of SF by LM-111 and TGF-β1 enhanced the production of IL-6 (7.8 ng/ml ± 5, *p*\<0.005) and IL-8 (73 ng/mL ± 51.3, *p*\<0.04) to some degree. The data represent the mean values ± standard deviations of supernatants from n≤6 SF from RA and OA patients.](IJBS-06-289-g002){#F2}

Biological activity of fibroblast-produced IL-6 and IL-8
--------------------------------------------------------

To further confirm the relevance of our studies we investigated the proliferation of B9 B-cells, which are highly dependent of IL-6. Supernatants from activated SF increased the number of viable B9 cells as determined in an MTT assay by 16% compared to medium as a control (Table [2](#T2){ref-type="table"}). The biological activity of IL-8 produced by the activated SF was determined in a cell migration assay. The supernatants of activated SF increased the number of migrating HL60 myeloma cells 2.2-fold in comparison to controls (Table [2](#T2){ref-type="table"}). We conclude that the IL-6 and IL-8 produced by SF after this activation were biologically active.

###### 

Investigation of biological activity of IL-6 and IL-8 in supernatants of activated SF

  Cytokine   SF supernatant   Neg. control   Pos. control
  ---------- ---------------- -------------- --------------
                                             
  IL-6         1.16           1                2.19
  IL-8         2.2            1                2.3

SF were activated by TGF-β1 and attachment to LM-111 for 24 h. The supernatants were harvested, pre-cleared by centrifugation and the biological activity was determined. IL-6 was detected utilizing the IL-6 dependent proliferation of B9 hybrodima cells, IL-8 by cell migration of HL-60 myeloma cells. DMEM complete medium without addition of cytokines served as negative controls, DMEM complete medium enriched with recombinant IL-6 or IL-8 served as positive controls.

DISCUSSION
==========

Activation of SF by attachment to LM-111 in presence of TGF-β1 induced an elevated expression of IL-6 and IL-8, without involving IL-1β or TNF-α. The expression of TNF-α and IL-1β is especially elevated during an acute phase of rheumatoid arthritis. In this stage transcription factor NFκB serves as an important switch, regulating a variety of cytokines, proteases and other mediators associated with synovitis in RA, including IL-1β, IL-6 and IL-8 ([@R5], [@R19]). In contrast, the TGF-β1 plus LM-111 dependent activation of SF does not seem to be an important trigger in acute inflammatory processes. But this TGF-β1-dependent pathway may maintain a chronic inflammation independent of or after acute flare, albeit at low or moderate levels. It may also contribute to the activation of SF during or after capture of IL-1β or TNF-α by so-called biologicals, such as anakinra, infliximab, etanercept, adalibumab or alike. The TGF-β1 plus LM-111-activated SF produced 6--8 ng/ml of IL-6 and about 70 ng/ml of IL-8 *in vitro* within 24 h of stimulation. This is within the range reported for IL-6 in RA synovial fluid or plasma ([@R15]), and more than reported for IL-8 in RA synovial fluid ([@R16]) or plasma ([@R20]).

In contrast to IL-16 ([@R14]), the regulation of IL-6 or IL-8 by TGF-β1 plus LM-111 did not significantly differ between RA-SF and OA-SF (not shown), suggesting that this mode of regulation of IL-6 and IL-8 is not a specific feature of RA. This finding supports our notion that TGF-β1 and LM-111 may regulate IL-6 and IL-8 expression in SF independently of acute inflammation. Moreover, the RA patients were not in an active stage of flare-up at the time point of surgical treatment. This suggests that inflammation characterized by elevated production of IL-1 or TNF-α are not involved in the regulatory pathways described above.

But TGF-β1 is detected in both, RA and OA synovial fluid ([@R21]). Elevated expression of different laminin chains in the synovial membrane is more pronounced in RA than in OA samples, but direct proof for over-expression of the a1- and g1 chains of LM-111 is missing ([@R12]). On the other hand, LM-111 was described recently as a component of articular cartilage, which is enriched in the pericellular zone in particular ([@R11]). Components of the pericellular matrix of cartilage may be exposed to SF during degenerative processes or after injury, and thus contribute to an inflammatory process fuelled by LM-111 or laminin-derived fragments originating from cartilage.

In summary, we provide evidence that binding of synovial fibroblasts to LM-111 in the presence of TGF-β1 triggers a moderate but significant response of IL-6 and IL-8. This pathway seems not to contribute to the pathology of arthritis during the stages of flare-up and acute inflammation, but may well propagate chronic catabolic processes in a joint, even when IL-1β or TNF-α are not expressed at pathological levels or are captured pharmacologically.
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